LAVA Medtech Acquisition Corp. Class A Common Stock
LVAC
LVAC was delisted on the 10th of May, 2023.
54 hedge funds and large institutions have $107M invested in LAVA Medtech Acquisition Corp. Class A Common Stock in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 6 closing their positions.
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
12% more capital invested
Capital invested by funds: $95.3M → $107M (+$11.4M)
10% more funds holding
Funds holding: 49 → 54 (+5)
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Castle Creek Arbitrage
Avon,
Colorado
|
+$6.07M |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$2.61M |
| 3 |
CCM
Context Capital Management
Lajolla,
California
|
+$2.28M |
| 4 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
+$542K |
| 5 |
EC
Elequin Capital
New York
|
+$506K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$2.77M |
| 2 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$1.45M |
| 3 |
CM
Cohanzick Management
Pleasantville,
New York
|
-$517K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$230K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$72K |
LVAC Hedge Fund Activity: Q4 2022 in Review
54 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) for Q4 2022, worth a combined $107M — up 12% from $95.3M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new LVAC positions and 6 closed out — a net gain of 5 holders — while 2 added to existing stakes and 8 trimmed.
The largest buyer was Castle Creek Arbitrage, opening a new position worth an estimated $6.07M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $2.77M sold.
- 54 institutional investors held LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) as of Q4 2022, up from 49 in Q3 2022.
- Funds reported $107M of LAVA Medtech Acquisition Corp. Class A Common Stock stock for Q4 2022, up 12% quarter-over-quarter.
- 11 funds opened new LAVA Medtech Acquisition Corp. Class A Common Stock positions in Q4 2022 and 6 closed out, a net change of +5 holders.
- The largest LAVA Medtech Acquisition Corp. Class A Common Stock buyer in Q4 2022 was Castle Creek Arbitrage, an estimated $6.07M added.
- The largest LAVA Medtech Acquisition Corp. Class A Common Stock seller in Q4 2022 was JP Morgan Chase, an estimated $2.77M sold.
Based on aggregated 13F filings for Q4 2022.